EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nutrition Intervention with High-Protein and β-Hydroxy-β-Methylbutyrate (HMB) Is Associated with Readmission Reduction and Cost Savings Among Patients with Malnutrition Risk

Sigal Frishman, Ronit Doyev, Maya Ben Lassan, Alina Rosenberg, Orly Weinstein, Amy R Sharn iD, Kirk W Kerr, Suela Sulo, Lihi Godny iD

Nutrients · 2025

DOI: 10.3390/nu17223511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Sigal Frishman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nutrition Department, Rabin Medical Center, Clalit Health Services, Petah Tikva 4941492, Israel. Hauptthemen laut MEDLINE: Valerates, Patient Readmission, Malnutrition, Cost Savings. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Nutrition (United States), Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Malnutrition in hospitalized older adults is associated with increased healthcare utilization, prolonged hospitalizations, and higher readmission rates. Specialized oral nutritional supplements enriched with β-hydroxy-β-methylbutyrate (HMB-ONS) have shown benefits in preserving muscle mass, improving functional outcomes, and reducing readmission rates, yet real-world data on their effectiveness remain limited. This study evaluated the association between HMB-ONS use and hospital readmission rates, as well as healthcare costs, in patients with malnutrition or at risk of malnutrition.

Methods

This retrospective study analyzed electronic medical records (2015–2021) of hospitalized patients at risk of malnutrition at two tertiary care hospitals in Israel. Patients receiving HMB-ONS during hospitalization were compared with those receiving standard ONS (S-ONS). Propensity score matching (PSM) was employed to reduce potential confounding due to differences in observable characteristics. Primary outcomes were readmission rates at 1-, 3-, and 6-month post-discharge. A cost analysis estimated per-patient hospitalization costs and financial savings from reduced readmissions.

Results

Of 391,838 hospitalizations, 16,751 patients met the inclusion criteria. Patients with malnutrition or at risk of malnutrition who received HMB-ONS during hospitalization were PSM-matched to those who received S-ONS (n = 1440, 53.5% female, average age of 78.25 (±15.62) years). Patients who received HMB-ONS had significantly lower odds of readmission compared with those receiving S-ONS at 1 month (OR = 0.698; 95% CI: 0.548–0.888; p = 0.0034), 3 months (OR = 0.772; 95% CI: 0.623–0.958; p = 0.0187), and 6 months (OR = 0.780; 95% CI: 0.633–0.961; p = 0.0195). Based on these differences, the economic analysis estimated net cost savings of EUR 387.61 (USD 403.29) per patient for HMB-ONS versus S-ONS.

Conclusions

HMB-ONS was associated with significantly lower readmission rates and healthcare costs compared to S-ONS in patients with malnutrition or at risk of malnutrition. These findings may support the use of specialized nutritional interventions to improve clinical outcomes and optimize hospital resource utilization in patients with malnutrition or at risk of malnutrition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValeratesPatient ReadmissionMalnutritionCost SavingsDietary SupplementsDietary ProteinsHumansFemaleMaleAgedRetrospective StudiesAged, 80 and overHospitalizationIsraelMiddle Aged

Stichwörter der Autor:innen

beta-hydroxy-beta-methylbutyrate (HMB)cost-savingshospital readmissionsmalnutritionnutritional interventionoral nutritional supplements (ONS)

Substanzen

Valeratesbeta-hydroxyisovaleric acidDietary Proteins

Autor:innen und Institutionen

  • Nutrition Department, Rabin Medical Center, Clalit Health Services, Petah Tikva 4941492, Israel.
  • Clalit Health Services, Tel Aviv 6209813, Israel.
  • Global Medical Affairs and Research, Abbott Nutrition, Tel Aviv 6935018, Israel.
  • Israel National Cancer Registry, Israel Ministry of Health, Jerusalem 9101002, Israel.
  • Israel Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan 5262100, Israel.
  • Faculty of Medicine, Ariel University, Ariel 4077625, Israel.

ORCID-Profile: Amy R Sharn, Lihi Godny

Förderung

  • Abbott Nutrition (United States)
  • Abbott Laboratories

Zitieren

APA

Frishman, S., Doyev, R., Ben Lassan, M., Rosenberg, A., Weinstein, O., Sharn, A. R., Kerr, K. W., Sulo, S., & Godny, L. (2025). Nutrition Intervention with High-Protein and β-Hydroxy-β-Methylbutyrate (HMB) Is Associated with Readmission Reduction and Cost Savings Among Patients with Malnutrition Risk. Nutrients. https://doi.org/10.3390/nu17223511

Vancouver

Frishman S, Doyev R, Ben Lassan M, Rosenberg A, Weinstein O, Sharn AR, et al. Nutrition Intervention with High-Protein and β-Hydroxy-β-Methylbutyrate (HMB) Is Associated with Readmission Reduction and Cost Savings Among Patients with Malnutrition Risk. Nutrients. 2025. doi:10.3390/nu17223511

BibTeX
@article{Frishman2025,
  author = {Frishman, Sigal and Doyev, Ronit and Ben Lassan, Maya and Rosenberg, Alina and Weinstein, Orly and Sharn, Amy R and Kerr, Kirk W and Sulo, Suela and Godny, Lihi},
  title = {Nutrition Intervention with High-Protein and β-Hydroxy-β-Methylbutyrate (HMB) Is Associated with Readmission Reduction and Cost Savings Among Patients with Malnutrition Risk},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17223511}
}
Kostenlos starten →